Anacetrapib

Anacetrapib

Names
Preferred IUPAC name (4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-{[4′-fluoro-2′-methoxy-5′-(propan-2-yl)-4-(trifluoromethyl)[1,1′-biphenyl]-2-yl]methyl}-4-methyl-1,3-oxazolidin-2-one
Other names MK-0859
Identifiers
CAS Number	875446-37-0  Y
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL1800807  N
ChemSpider	9731205  Y
KEGG	D08855  Y
PubChem CID	11556427
UNII	P7T269PR6S  Y
CompTox Dashboard (EPA)	DTXSID90236452
InChI InChI=1S/C30H25F10NO3/c1-14(2)22-11-23(25(43-4)12-24(22)31)21-6-5-18(28(32,33)34)9-17(21)13-41-15(3)26(44-27(41)42)16-7-19(29(35,36)37)10-20(8-16)30(38,39)40/h5-12,14-15,26H,13H2,1-4H3/t15-,26-/m0/s1 Y Key: MZZLGJHLQGUVPN-HAWMADMCSA-N Y InChI=1/C30H25F10NO3/c1-14(2)22-11-23(25(43-4)12-24(22)31)21-6-5-18(28(32,33)34)9-17(21)13-41-15(3)26(44-27(41)42)16-7-19(29(35,36)37)10-20(8-16)30(38,39)40/h5-12,14-15,26H,13H2,1-4H3/t15-,26-/m0/s1 Key: MZZLGJHLQGUVPN-HAWMADMCBN
SMILES O=C2O[C@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)[C@@H](N2Cc4c(c3cc(c(F)cc3OC)C(C)C)ccc(c4)C(F)(F)F)C
Properties
Chemical formula	C30H25F10NO3
Molar mass	637.51 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). N  verify  (what is  YN ?) Infobox references

Anacetrapib is a CETP inhibitor which was being developed to treat elevated cholesterol levels in an effort to prevent cardiovascular disease. ^[1] In 2017 its development was abandoned by Merck. ^[2]

Evidence

In 2017 REVEAL trial anacetrapib was shown to decrease the risk of repeat heart attacks in high-risk patients with previous acute coronary events. ^[3]

See also

Other CETP inhibitors:^{[ citation needed ]}

• Torcetrapib was developed by Pfizer until December 2006 but caused unacceptable increases in blood pressure and had net cardiovascular detriment.
• Dalcetrapib was developed by Hoffmann–La Roche until May 2012. It did not raise blood pressure and did raise HDL, but it showed no clinically meaningful efficacy.
• Evacetrapib was developed by Eli Lilly and Company until October 2015.

References

1. Gutstein DE, Krishna R, Johns D, et al. (2012). "Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction" . Clinical Pharmacology & Therapeutics. 91 (1): 109–122. doi:10.1038/clpt.2011.271. PMID   22130116. S2CID   36510986.
2. "Merck says will not seek approval of cholesterol treatment". Reuters. 2017. Retrieved 18 October 2017.
3. Filippatos, TD; Kei, A; Elisaf, MS (29 September 2017). "Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?". Diseases. 5 (4): 21. doi: 10.3390/diseases5040021 . PMC   5750532 . PMID   28961179.

Further reading

• WO 2007005572,Miller, Ross A.&Cote, Aaron S.,"Process for synthesizing a CETP inhibitor",published 2007-01-11, assigned to Merck & Co. Inc.